M&A
confidence high
sentiment positive
materiality 0.75
Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M
Context Therapeutics Inc.
- Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.
- CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.
- Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.
- Advancement through Phase 1 dose escalation to be funded with existing cash.